Zipsor is an anti-inflammatory drug owned by Assertio. This drug which contains diclofenac potassium was authorised for market use on 16 June, 2009. It is available in capsule oral dosage forms. Zipsor has a total of 6 drug patents, none of which have expired.
The generic version of Zipsor is expected to be available after 24 February, 2029. This release date takes into account the expiry of the drug's last patent held by Assertio.
Zipsor, with its active ingredient diclofenac potassium, is indicated for relief of mild to moderate acute pain. It specifically serves as a nonsteroidal anti-inflammatory drug.
Zipsor owns a total of 6 patents which all aim to treat post-surgical acute pain. The last patent is set to expire on 2029-02-24, which roughly specifies the release date of Zipsor generic. Below are the details of the patents: